RxDoctor Payments Data

Scott Dunitz, MD

Adult Reconstructive Orthopaedic Surgery · Tulsa, OKNPI 1316914542

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $180,400 of the $185,743 with a category attached, or 97.1%. Exactech, Inc. accounts for 99.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $180,431 and has fallen 99.9% since, to $129 in 2024.

$185,743in general payments, 2019–2025

Across 51 payments — averaging $3642.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exactech, Inc.$184K
  • Omnilife Science, Inc$405
  • Encore Medical, LP$159
  • Stryker$136
  • Pacira Therapeutics, Inc.$130
  • Total Joint Orthopedics, Inc.$98
  • plus $386 from 13 others
$57,698in research payments, 2019–2025

Across 6 payments — averaging $9616.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Exactech, Inc.$58K

What the payments were for

  • Royalty or licence$2,6621%
  • Speaking & faculty fees$180,40097%
  • Travel & lodging$1,1961%
  • Food & beverage$1,4851%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$265,826
Medicare patients
435
Services billed
3,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$10,087
Celecoxib68$1,548
Oxycodone Hcl195$1,473
Cephalexin198$932
Gabapentin119$805
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$639
Cefadroxil42$530
Methocarbamol123$529
Meloxicam69$364
Ondansetron Hcl121$343
Methylprednisolone38$284
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$278
Ciprofloxacin Hcl14$209
Tramadol Hcl32$119

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →